Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
June 26, 2023 07:00 ET
|
Marker Therapeutics
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on developing next-generation T...
Aptose Presents Highlights from Clinical Update
June 10, 2023 12:00 ET
|
Aptose Biosciences, Inc.
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat...
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
June 09, 2023 07:30 ET
|
Vor Biopharma
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust enrollment; additional data...
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
June 05, 2023 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman...
Melissa Points to Real-Time Data Quality as Key to Compliance Initiatives in Online Gambling
May 31, 2023 08:00 ET
|
Melissa
RANCHO SANTA MARGARITA, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Melissa, a leading provider of global data quality, identity verification, and address management solutions, today cited clean data...
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
May 11, 2023 16:05 ET
|
Vor Biopharma
VBP101 clinical data update planned at European Hematology Association (EHA) 2023VCAR33ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:...
Kura Oncology Reports First Quarter 2023 Financial Results
May 10, 2023 16:03 ET
|
Kura Oncology, Inc.
– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML...
Quantexa Provides ING with Solution to Strengthen and Automate Global Risk Coverage
May 10, 2023 08:00 ET
|
Quantexa
LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Today Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced that ING is deploying Quantexa’s...
Kura Oncology to Participate in JMP Securities Life Sciences Conference
May 09, 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Oncotelic Launches PDAO SEC Chatbot
April 24, 2023 07:30 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), , today announced the beta launch of a proprietary...